Dangerous liaisons

Doctors-in-training and the pharmaceutical industry

A. M.J. Pokorny, C. B. Gittins

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Interaction between doctors and the pharmaceutical industry is long-standing and ingrained in modern practice. Doctors-in-training are at a vulnerable stage of their careers, both in requiring knowledge and forming lasting relationships. There is evidence that limiting contact between industry and junior doctors has a positive effect on subsequent clinical behaviour. Currently in Australia, there is no limitation on pharmaceutical representatives approaching doctors-in-training, and the majority of education sessions are sponsored by pharmaceutical companies. This purposefully creates a sense of reciprocity, which may have adverse long-term consequences on attitudes, behaviours and patient care. Several guidelines exist that may assist junior doctors in navigating these potential interactions, most notably the Royal Australasian College of Physicians' own Guidelines for Ethical Relationships between Physicians and Industry. Despite this, there is no reflection of its importance or necessity within subspecialty curricula. This should be rectified, to the benefit of both the profession and public.

Original languageEnglish
Pages (from-to)1085-1088
Number of pages4
JournalInternal Medicine Journal
Volume45
Issue number10
DOIs
Publication statusPublished - Oct 2015
Externally publishedYes

Fingerprint

Drug Industry
Industry
Guidelines
Physicians
Pharmaceutical Preparations
Curriculum
Patient Care
Education

Cite this

Pokorny, A. M.J. ; Gittins, C. B. / Dangerous liaisons : Doctors-in-training and the pharmaceutical industry. In: Internal Medicine Journal. 2015 ; Vol. 45, No. 10. pp. 1085-1088.
@article{0ce85d2570ad4ce6b06e83136b5bef00,
title = "Dangerous liaisons: Doctors-in-training and the pharmaceutical industry",
abstract = "Interaction between doctors and the pharmaceutical industry is long-standing and ingrained in modern practice. Doctors-in-training are at a vulnerable stage of their careers, both in requiring knowledge and forming lasting relationships. There is evidence that limiting contact between industry and junior doctors has a positive effect on subsequent clinical behaviour. Currently in Australia, there is no limitation on pharmaceutical representatives approaching doctors-in-training, and the majority of education sessions are sponsored by pharmaceutical companies. This purposefully creates a sense of reciprocity, which may have adverse long-term consequences on attitudes, behaviours and patient care. Several guidelines exist that may assist junior doctors in navigating these potential interactions, most notably the Royal Australasian College of Physicians' own Guidelines for Ethical Relationships between Physicians and Industry. Despite this, there is no reflection of its importance or necessity within subspecialty curricula. This should be rectified, to the benefit of both the profession and public.",
keywords = "Doctor-in-training, Ethics, Pharmaceutical industry",
author = "Pokorny, {A. M.J.} and Gittins, {C. B.}",
year = "2015",
month = "10",
doi = "10.1111/imj.12855",
language = "English",
volume = "45",
pages = "1085--1088",
journal = "Internal Medicine Journal",
issn = "1444-0903",
publisher = "Wiley-Blackwell",
number = "10",

}

Dangerous liaisons : Doctors-in-training and the pharmaceutical industry. / Pokorny, A. M.J.; Gittins, C. B.

In: Internal Medicine Journal, Vol. 45, No. 10, 10.2015, p. 1085-1088.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Dangerous liaisons

T2 - Doctors-in-training and the pharmaceutical industry

AU - Pokorny, A. M.J.

AU - Gittins, C. B.

PY - 2015/10

Y1 - 2015/10

N2 - Interaction between doctors and the pharmaceutical industry is long-standing and ingrained in modern practice. Doctors-in-training are at a vulnerable stage of their careers, both in requiring knowledge and forming lasting relationships. There is evidence that limiting contact between industry and junior doctors has a positive effect on subsequent clinical behaviour. Currently in Australia, there is no limitation on pharmaceutical representatives approaching doctors-in-training, and the majority of education sessions are sponsored by pharmaceutical companies. This purposefully creates a sense of reciprocity, which may have adverse long-term consequences on attitudes, behaviours and patient care. Several guidelines exist that may assist junior doctors in navigating these potential interactions, most notably the Royal Australasian College of Physicians' own Guidelines for Ethical Relationships between Physicians and Industry. Despite this, there is no reflection of its importance or necessity within subspecialty curricula. This should be rectified, to the benefit of both the profession and public.

AB - Interaction between doctors and the pharmaceutical industry is long-standing and ingrained in modern practice. Doctors-in-training are at a vulnerable stage of their careers, both in requiring knowledge and forming lasting relationships. There is evidence that limiting contact between industry and junior doctors has a positive effect on subsequent clinical behaviour. Currently in Australia, there is no limitation on pharmaceutical representatives approaching doctors-in-training, and the majority of education sessions are sponsored by pharmaceutical companies. This purposefully creates a sense of reciprocity, which may have adverse long-term consequences on attitudes, behaviours and patient care. Several guidelines exist that may assist junior doctors in navigating these potential interactions, most notably the Royal Australasian College of Physicians' own Guidelines for Ethical Relationships between Physicians and Industry. Despite this, there is no reflection of its importance or necessity within subspecialty curricula. This should be rectified, to the benefit of both the profession and public.

KW - Doctor-in-training

KW - Ethics

KW - Pharmaceutical industry

UR - http://www.scopus.com/inward/record.url?scp=84942894492&partnerID=8YFLogxK

U2 - 10.1111/imj.12855

DO - 10.1111/imj.12855

M3 - Article

VL - 45

SP - 1085

EP - 1088

JO - Internal Medicine Journal

JF - Internal Medicine Journal

SN - 1444-0903

IS - 10

ER -